Cocktail approach for in vivo phenotyping of 5 major CYP450 isoenzymes: Development of an effective sampling, extraction, and analytical procedure and pilot study with comparative genotyping

Journal of Clinical Pharmacology

Volumn 52, Issue 8, 2012, Pages 1200-1214

  Wohlfarth, Ariane ^a   Naue, Jana ^a   Lutz Bonengel, Sabine ^a   Dresen, Sebastian ^b   Auwärter, Volker ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

cocktail; CYP enzymes; CYP1A2; CYP2C19; CYP2C9; CYP2D6; CYP3A; genotyping; LC MS MS; Phenotyping

Indexed keywords

AMMONIUM ACETATE; CAFFEINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; METHANOL; MIDAZOLAM; OMEPRAZOLE; TOLBUTAMIDE;

ACCURACY; ADULT; ANALYTIC METHOD; ARTICLE; ASSAY; BLOOD SAMPLING; CALIBRATION; CONTROLLED STUDY; ELECTROSPRAY; ELUTION; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; INTERMETHOD COMPARISON; ION TRAP MASS SPECTROMETRY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; NUCLEOTIDE SEQUENCE; PHENOTYPE; PILOT STUDY; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

ADULT; CAFFEINE; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DEXTROMETHORPHAN; FEMALE; GENOTYPE; HUMANS; ISOENZYMES; MALE; MIDAZOLAM; OMEPRAZOLE; PHENOTYPE; PILOT PROJECTS; TANDEM MASS SPECTROMETRY; TOLBUTAMIDE; YOUNG ADULT;

EID: 84864399895     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011410570     Document Type: Article

References (26)

1. Frye RF, Matzke GR, Adedoyin A, Porter JA, Branch RA. Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. Clin Pharmacol Ther. 1997 ; 62 (4). 365-376 (Pubitemid 27475220)
2. Petsalo A, Turpeinen M, Pelkonen O, Tolonen A. Analysis of nine drugs and their cytochrome P450-specific probe metabolites from urine by liquid chromatography-tandem mass spectrometry utilizing sub 2 microm particle size column. J Chromatogr A. 2008 ; 1215 (1-2). 107-115
3. Streetman DS, Bertino JS, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics. 2000 ; 10 (3). 187-216 (Pubitemid 30242736)
4. Rodrigues AD Drug-Drug Interactions. 2 nd ed.New York: Informa Healthcare; 2008. New York: Informa Healthcare ; 2008:
5. Fuhr U, Jetter A, Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach. Clin Pharmacol Ther. 2007 ; 81 (2). 270-283 (Pubitemid 46174825)
6. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999 ; 286 (5439). 487-491
7. Zhou H, Tong Z, McLeod JF. "Cocktail" approaches and strategies in drug development: valuable tool or flawed science?. J Clin Pharmacol. 2004 ; 44 (2). 120-134 (Pubitemid 38114310)
8. Ghassabian S, Chetty M, Tattam BN, et al. A high-throughput assay using liquid chromatography-tandem mass spectrometry for simultaneous in vivo phenotyping of 5 major cytochrome p450 enzymes in patients. Ther Drug Monit. 2009 ; 31 (2). 239-246
9. Yin OQ, Lam SS, Lo CM, Chow MS. Rapid determination of five probe drugs and their metabolites in human plasma and urine by liquid chromatography/tandem mass spectrometry: application to cytochrome P450 phenotyping studies. Rapid Commun Mass Spectrom. 2004 ; 18 (23). 2921-2933 (Pubitemid 39576836)
10. Jetter A, Kinzig-Schippers M, Skott A, et al. Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. Eur J Clin Pharmacol. 2004 ; 60 (3). 165-171 (Pubitemid 38757127)
11. Ryu JY, Song IS, Sunwoo YE, et al. Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo. Clin Pharmacol Ther. 2007 ; 82 (5). 531-540 (Pubitemid 47622519)
12. Hu OY, Tang HS, Lane HY, Chang WH, Hu TM. Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity. J Pharmacol Exp Ther. 1998 ; 285 (3). 955-960 (Pubitemid 28277890)
13. Borges S, Li L, Hamman MA, Jones DR, Hall SD, Gorski JC. Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance. Drug Metab Dispos. 2005 ; 33 (7). 1052-1055 (Pubitemid 41002788)
14. Lin YS, Lockwood GF, Graham MA, et al. In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics. 2001 ; 11 (9). 781-791 (Pubitemid 33151513)
15. Peters FT, Drummer OH, Musshoff F. Validation of new methods. Forensic Sci Int. 2007 ; 165 (2-3). 216-224 (Pubitemid 46073540)
16. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem. 2003 ; 75 (13). 3019-3030 (Pubitemid 36830428)
17. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol. 2001 ; 41: 815-850 (Pubitemid 32385908)
18. Tribut O, Lessard Y, Reymann JM, Allain H, Bentue-Ferrer D. Pharmacogenomics. Med Sci Monit. 2002 ; 8 (7). RA152 - RA163
19. Palatini P, Ceolotto G, Ragazzo F, et al. CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension. J Hypertens. 2009 ; 27 (8). 1594-1601
20. Bozina N, Bradamante V, Lovric M. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Arh Hig Rada Toksikol. 2009 ; 60 (2). 217-242
21. Goldstein JA, Blaisdell J. Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Methods Enzymol. 1996 ; 272: 210-218 (Pubitemid 26299884)
22. Zhu B, Ou-Yang DS, Chen XP, et al. Assessment of cytochrome P450 activity by a five-drug cocktail approach. Clin Pharmacol Ther. 2001 ; 70 (5). 455-461 (Pubitemid 33135325)
23. Scott RJ, Palmer J, Lewis IA, Pleasance S. Determination of a "GW cocktail" of cytochrome P450 probe substrates and their metabolites in plasma and urine using automated solid phase extraction and fast gradient liquid chromatography tandem mass spectrometry. Rapid Commun Mass Spectrom. 1999 ; 13 (23). 2305-2319
24. Christensen M, Andersson K, Dalen P, et al. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther. 2003 ; 73 (6). 517-528 (Pubitemid 37249122)
25. Chainuvati S, Nafziger AN, Leeder JS, et al. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase- 2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". Clin Pharmacol Ther. 2003 ; 74 (5). 437-447 (Pubitemid 37357722)
26. Blakey GE, Lockton JA, Perrett J, et al. Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1. Br J Clin Pharmacol. 2004 ; 57 (2). 162-169 (Pubitemid 38223528)